NASDAQ:BLTE

Belite Bio - BLTE Stock Forecast, Price & News

$27.01

+0.13 (+0.48%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $27.00
▼
$28.00
50-Day Range: $25.61
▼
$33.50
52-Week Range: $8.80
▼
$44.70

Volume: 17,109 shs
Average Volume: 13,908 shs
Market Capitalization: $672.55 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $57.50

Institutional Ownership

Belite Bio MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 112.9% Upside
$57.50 Price Target
Short Interest: Healthy
0.16% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

199th out of 1,005 stocks

Pharmaceutical Preparations Industry

83rd out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
Belite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $57.50, Belite Bio has a forecasted upside of 112.9% from its current price of $27.01.
Amount of Analyst Coverage
Belite Bio has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.16% of the outstanding shares of Belite Bio have been sold short.
Short Interest Ratio / Days to Cover
Belite Bio has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Belite Bio has recently increased by 1.84%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Belite Bio does not currently pay a dividend.
Dividend Growth
Belite Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLTE.

2.7

News and Social Media Coverage

News Sentiment
Belite Bio has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Belite Bio this week, compared to 0 articles on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Belite Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 0.46% of the stock of Belite Bio is held by institutions.

N/A

Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

About Belite Bio (NASDAQ:BLTE) Stock

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Receive BLTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter.

BLTE Stock News Headlines

March 23, 2023 | americanbankingnews.com

Belite Bio (NASDAQ:BLTE) Sees Large Volume Increase

January 25, 2023 | wsj.com

Belite Bio Inc. ADR

March 26, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

October 20, 2022 | finance.yahoo.com

Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data

October 1, 2022 | finance.yahoo.com

Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022

September 18, 2022 | seekingalpha.com

Belite Bio receives approval of begin LBS-008 phase 3 trial in China

September 16, 2022 | finance.yahoo.com

Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China

August 23, 2022 | seekingalpha.com

Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.

March 26, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

August 22, 2022 | markets.businessinsider.com

Belite Bio Shares Gain On Initiation Of Late-Stage Retinal Disease Study

August 13, 2022 | seekingalpha.com

Belite Bio, Inc's (BLTE) CEO Tom Lin on Q2 2022 Results - Earnings Call Transcript

August 3, 2022 | nasdaq.com

Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans

August 1, 2022 | finance.yahoo.com

'Novel Approach For Retinal Disease Needs' Stock Belite Bio Has 70% Potential Upside According To This Analyst

August 1, 2022 | finance.yahoo.com

Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results

July 30, 2022 | finance.yahoo.com

We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

July 19, 2022 | markets.businessinsider.com

Belite Bio Seeks FDA Clearance For Late-Stage Genetic Eye Disease Study

July 19, 2022 | finance.yahoo.com

Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease

July 3, 2022 | benzinga.com

Belite Bio (NASDAQ:BLTE), Analyst Ratings, Price Targets, Predictions

July 1, 2022 | seekingalpha.com

Hot Stocks: META dips on curtailed hiring; PCT dips on CEO departure; ACCD earnings; BLTE gets Buy rating

July 1, 2022 | seekingalpha.com

Belite Bio initiated with a Buy at Benchmark

June 17, 2022 | seekingalpha.com

Evoke, Zynerba top healthcare gainers; while 180 Life, Belite Bio lead losers' pack

June 14, 2022 | morningstar.com

Belite Bio Inc ADR - Stock Quote BLTE

June 13, 2022 | seekingalpha.com

Belite Bio jumps 13%, now trading 247% above IPO price

May 21, 2022 | finanznachrichten.de

Belite Bio, Inc: Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering

May 15, 2022 | investing.com

Belite Bio Inc ADR (BLTE)

May 9, 2022 | finance.yahoo.com

Belite Bio Receives FDA Fast Track Designation For LBS-008

May 9, 2022 | finance.yahoo.com

Belite Bio Announces Closing of $36 Million Initial Public Offering

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BLTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter.

BLTE Company Calendar

Today: 3/26/2023
Next Earnings (Estimated): 5/05/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BLTE
CUSIP: N/A
CIK: 1889109
Web: belitebio.com
Phone: 858-246-6240
Fax: N/A
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $57.50
High Stock Price Forecast: $58.00
Low Stock Price Forecast: $57.00
Forecasted Upside/Downside: +112.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 35.01
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 24,900,000
Free Float: 21,590,000
Market Cap: $672.55 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. Yu-Hsin Lin M.B.A. (Age 45)
Ph.D., Chairman of Directors & CEO

Mr. Hao-Yuan Chuang C.F.A. (Age 39)
F.R.M., M.B.A., CFO & Director

Dr. Nathan L. Mata Ph.D. (Age 57)
Chief Scientific Officer

Ms. Ching-Chen Chiu M.Sc. (Age 53)
VP of Clinical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BLTE Stock - Frequently Asked Questions

Should I buy or sell Belite Bio stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Belite Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BLTE shares.
View BLTE analyst ratings or view top-rated stocks.
What is Belite Bio's stock price forecast for 2023?: 2 equities research analysts have issued 12 month target prices for Belite Bio's shares. Their BLTE share price forecasts range from $57.00 to $58.00. On average, they expect the company's stock price to reach $57.50 in the next year. This suggests a possible upside of 112.9% from the stock's current price.
View analysts price targets for BLTE or view top-rated stocks among Wall Street analysts.
How have BLTE shares performed in 2023?: Belite Bio's stock was trading at $30.1450 on January 1st, 2023. Since then, BLTE shares have decreased by 10.4% and is now trading at $27.01.
View the best growth stocks for 2023 here.
When is Belite Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our BLTE earnings forecast.
What ETF holds Belite Bio's stock ?: ALPS Medical Breakthroughs ETF holds 16,217 shares of BLTE stock, representing 0.49% of its portfolio.
When did Belite Bio IPO?: (BLTE) raised $36 million in an IPO on Friday, April 29th 2022. The company issued 6,000,000 shares at a price of $5.50-$6.50 per share.

What is Belite Bio's stock symbol?: Belite Bio trades on the NASDAQ under the ticker symbol "BLTE."
Who are Belite Bio's major shareholders?: Belite Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include Atria Wealth Solutions Inc. (3.26%), Alps Advisors Inc. (0.06%), UBS Group AG (0.02%) and Morgan Stanley (0.01%).
How do I buy shares of Belite Bio?: Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Belite Bio's stock price today?: One share of BLTE stock can currently be purchased for approximately $27.01.
How much money does Belite Bio make?: Belite Bio (NASDAQ:BLTE) has a market capitalization of $672.55 million.
How can I contact Belite Bio?: The official website for the company is belitebio.com. The company can be reached via phone at 858-246-6240 or via email at ir@belitebio.com.

This page (NASDAQ:BLTE) was last updated on 3/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Belite Bio - BLTE Stock Forecast, Price & News

Belite Bio MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Belite Bio (NASDAQ:BLTE) Stock

BLTE Stock News Headlines

BLTE Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

BLTE Stock - Frequently Asked Questions

Overall MarketRank^™